Epigenomics and DxS Enter Into Strategic Cross-Licensing Agreement for the Use of Scorpions Technology in DNA Methylation

15-Jan-2008

Epigenomics AG (and DxS Ltd. announced that they have entered into a strategic cross-licensing agreement. Under the terms of the agreement, Epigenomics obtains worldwide non-exclusive rights to DxS' proprietary Scorpions® technology for R&D use and research kits, as well as an option to expand the license to the in vitro diagnostics (IVD) field. Epigenomics intends to use this technology both in certain research kits as well as potentially in its cancer specialty diagnostics products. DxS in return receives an option for a worldwide non-exclusive license and further options to certain Epigenomics IP covering the use of Scorpions® technology for DNA methylation applications. Both Epigenomics and DxS have acquired options to sub-licensing rights for the respective technologies.

Further details and financial terms of the agreement were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper